Indication

For the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor

Medicine details

Medicine name:
autologous anti-CD19-transduced CD3+ cells (KTE-X19) (Tecartus)
SMC ID:
SMC2351
Pharmaceutical company
Kite Pharma, a Gilead Company
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
09 August 2021
SMC meeting date:
06 July 2021
Patient group submission deadline:
03 May 2021